L
Lu Si
Researcher at Peking University
Publications - 197
Citations - 3390
Lu Si is an academic researcher from Peking University. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 23, co-authored 131 publications receiving 2121 citations. Previous affiliations of Lu Si include Capital Medical University.
Papers
More filters
Journal ArticleDOI
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.
TL;DR: Prognoses of patients with malignant melanoma diagnosed in China were suboptimal, and most patients were diagnosed with locally advanced disease, and ALM and MCM are the two most commonly diagnosed pathological subtypes.
Journal ArticleDOI
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Yan Kong,Lu Si,Yanyan Zhu,Xiaowei Xu,Christopher L. Corless,Keith T. Flaherty,Li Li,Haifu Li,Xinan Sheng,Chuanliang Cui,Zhihong Chi,Siming Li,Mei Han,Lili Mao,Aiping Lu,Jun Guo +15 more
TL;DR: This study suggests that increases in KIT gene copy numbers, but not KIT mutations, may be correlated to CD117 overexpression, and suggests that genetic KIT aberration is an adverse prognostic factor for melanoma.
Journal ArticleDOI
Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort
Lu Si,Yan Kong,Xiaowei Xu,Keith T. Flaherty,Xinan Sheng,Chuanliang Cui,Zhihong Chi,Siming Li,Lili Mao,Jun Guo +9 more
TL;DR: A clinical trial of kinase inhibitors targeting BRAF V600E in Chinese and Asian melanoma patients is warranted, and mutation in BRAF or NRAS gene is indicator for poor prognosis.
Journal ArticleDOI
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Felicity Newell,Yan Kong,James S. Wilmott,Peter Johansson,Peter M. Ferguson,Chuanliang Cui,Zhongwu Li,Stephen H. Kazakoff,Hazel Burke,Tristan J. Dodds,Ann-Marie Patch,Katia Nones,Varsha Tembe,Ping Shang,Louise van der Weyden,Kim Wong,Oliver Holmes,Serigne Lo,Conrad Leonard,Scott Wood,Qinying Xu,Robert V. Rawson,Robert V. Rawson,Pamela Mukhopadhyay,Reinhard Dummer,Mitchell P. Levesque,Göran Jönsson,Xuan Wang,Iwei Yeh,Hong Wu,Nancy M. Joseph,Boris C. Bastian,Georgina V. Long,Georgina V. Long,Andrew J. Spillane,Kerwin F. Shannon,John F. Thompson,John F. Thompson,Robyn P. M. Saw,David J. Adams,Lu Si,John V. Pearson,Nicholas K. Hayward,Nicola Waddell,Graham J. Mann,Jun Guo,Richard A. Scolyer,Richard A. Scolyer +47 more
TL;DR: A genomic landscape analysis of samples collected from three continents reveals a potential role for CDK4/6 or MEK inhibition in the treatment of the disease.
Journal ArticleDOI
Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Bin Lian,Lu Si,Chuanliang Cui,Zhihong Chi,Xinan Sheng,Lili Mao,Siming Li,Yan Kong,Bixia Tang,Jun Guo +9 more
TL;DR: In this article, the authors conducted a randomized phase II clinical trial in patients with resected mucosal melanoma to compare the efficacy and safety of high-dose IFN-α2b (HDI) and temozolomide-based chemotherapy as adjuvant therapy.